Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Chemokine receptor CCR5 in interferon-treated multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Circulating nociceptin and CGRP in medication-overuse headache

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neurostimulation for the treatment of chronic migraine and cluster headache

    Research output: Contribution to journalReviewResearchpeer-review

  3. Optical coherence tomography in acute optic neuritis: A population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Married, unmarried, divorced, and widowed and the risk of stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
OBJECTIVE: To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta). METHODS: The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 were analyzed in 109 patients with relapsing-remitting MS treated with IFN-beta who were followed clinically for 1 year. Cellular CCR5 expression was measured by flow cytometry. RESULTS: Patients with MS had a higher percentage of CCR5-positive monocytes than healthy controls. Increased monocyte expression of CCR5 correlated weakly with an increased short-term relapse risk but there was no relationship between CCR5 Delta32 allele and CCR5 promoter polymorphism genotypes and relapse risk. CONCLUSIONS: The results do not support a major role of CCR5 in the pathogenesis of relapses in MS patients treated with IFN-beta, but it is possible that monocyte CCR5 expression may be used as a marker of disease activity.
Original languageEnglish
JournalActa Neurologica Scandinavica
Volume115
Issue number6
Pages (from-to)413-8
Number of pages5
ISSN0001-6314
DOIs
Publication statusPublished - 2007

    Research areas

  • Adult, Biological Markers, Central Nervous System, DNA Mutational Analysis, Female, Gene Frequency, Genetic Markers, Genetic Predisposition to Disease, Genetic Screening, Genotype, Humans, Interferon-beta, Interferons, Male, Middle Aged, Monocytes, Multiple Sclerosis, Relapsing-Remitting, Mutation, Polymorphism, Genetic, Promoter Regions, Genetic, Receptors, CCR5

ID: 32535310